Opal Capital LLC Purchases 23,734 Shares of Zoetis Inc. $ZTS

Opal Capital LLC boosted its position in shares of Zoetis Inc. (NYSE:ZTS) by 1,388.8% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 25,443 shares of the company’s stock after buying an additional 23,734 shares during the period. Opal Capital LLC’s holdings in Zoetis were worth $3,008,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in ZTS. Prosperity Bancshares Inc bought a new stake in shares of Zoetis during the 4th quarter worth approximately $25,000. Cassaday & Co Wealth Management LLC acquired a new position in Zoetis during the first quarter valued at approximately $28,000. Lodestone Wealth Management LLC acquired a new position in Zoetis during the fourth quarter valued at approximately $30,000. Root Financial Partners LLC lifted its stake in Zoetis by 66.5% during the first quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after purchasing an additional 103 shares during the last quarter. Finally, Elyxium Wealth LLC acquired a new stake in shares of Zoetis in the 4th quarter valued at $32,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Zoetis

In other Zoetis news, Director Paul Bisaro acquired 2,000 shares of Zoetis stock in a transaction that occurred on Wednesday, May 13th. The shares were bought at an average price of $75.88 per share, with a total value of $151,760.00. Following the completion of the purchase, the director directly owned 27,862 shares in the company, valued at $2,114,168.56. This trade represents a 7.73% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Michael B. Mccallister acquired 3,000 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was bought at an average price of $77.76 per share, with a total value of $233,280.00. Following the completion of the acquisition, the director directly owned 24,524 shares of the company’s stock, valued at $1,906,986.24. This trade represents a 13.94% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders have acquired 11,650 shares of company stock worth $886,384. Company insiders own 0.22% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. TD Cowen dropped their price objective on Zoetis from $150.00 to $104.00 and set a “buy” rating for the company in a research report on Tuesday, June 30th. UBS Group dropped their target price on shares of Zoetis from $99.00 to $85.00 and set a “neutral” rating for the company in a report on Monday. Wall Street Zen lowered shares of Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Stifel Nicolaus dropped their price objective on shares of Zoetis from $95.00 to $85.00 and set a “hold” rating for the company in a research note on Friday, June 26th. Finally, JPMorgan Chase & Co. cut their target price on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Eight investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $118.33.

Zoetis Stock Performance

NYSE:ZTS opened at $77.51 on Wednesday. The stock’s 50-day moving average is $77.24 and its 200-day moving average is $103.37. Zoetis Inc. has a 1-year low of $71.47 and a 1-year high of $160.48. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80. The stock has a market cap of $32.49 billion, a P/E ratio of 12.85, a price-to-earnings-growth ratio of 1.20 and a beta of 0.75.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. During the same quarter last year, the business earned $1.48 EPS. The firm’s quarterly revenue was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Equities research analysts anticipate that Zoetis Inc. will post 6.87 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date is Monday, July 20th. Zoetis’s payout ratio is 35.16%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.